Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement

[No abstract available]

Авторы
Tereshchenko S.N. 1, 2 , Shestakova M.V.3 , Ageev F.T.1 , Galstyan G.R.3 , Galyavich A.S. 4 , Glezer M.G. 5 , Zhirov I.V.1, 2 , Karpov Y.A.1 , Kobalava Z.D. 6 , Matskeplishvili S.T.7
Журнал
Russian Journal of Cardiology
Издательство
Silicea-Poligraf
Номер выпуска
5
Язык
Русский
Страницы
114-120
Статус
Опубликовано
Ссылка
Внешняя ссылка
DOI
10.15829/1560-4071-2020-3919
Номер
3919
Том
25
Год
2020
Организации
  • 1 National Medical Research Center of Cardiology, Moscow, Russian Federation
  • 2 Russian Academy of Postgraduate Medical Education, Moscow, Russian Federation
  • 3 National Medical Research Center for Endocrinology, Moscow, Russian Federation
  • 4 Kazan State Medical University, Kazan, Russian Federation
  • 5 I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
  • 6 Peoples’ Friendship University of Russia, Moscow, Russian Federation
  • 7 Medical Research and Educational Center, Moscow State University, Moscow, Russian Federation
Ключевые слова
DAPA-HF trial; Dapagliflozin; Heart failure with reduced ejection fraction
Дата создания
02.11.2020
Дата изменения
02.11.2020
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/65662/
Поделиться

Другие записи